The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS Serotonin (5-hydroxytryptamine [5-HT]) has an important role in gastrointestinal function. LX1031 is an oral, locally acting, small molecule inhibitor of tryptophan hydroxylase (TPH). Local inhibition of TPH in the gastrointestinal tract might reduce mucosal production of serotonin (5-HT) and be used to treat patients with nonconstipating irritable bowel syndrome (IBS). METHODS We evaluated 2 dose levels of LX1031 (250 mg or 1000 mg, given 4 times/day) in a 28-day, multicenter, randomized, double-blind, placebo-controlled study of 155 patients with nonconstipating IBS. 5-hydroxyindoleacetic acid (5-HIAA), a biomarker of pharmacodynamic activity, was measured in urine samples at baseline (24 hours after LX1031 administration), and at weeks 4 and 6 (n = 76). RESULTS Each dose of LX1031 was safe and well-tolerated. The primary efficacy end point, relief of IBS pain and discomfort, improved significantly in patients given 1000 mg LX1031 (25.5%), compared with those given placebo, at week 1 (P = .018); with nonsignificant improvements at weeks 2, 3, and 4 (17.9%, 16.3%, and 11.6%, respectively). Symptom improvement correlated with a dose-dependent reduction in 5-HIAA, a marker for TPH inhibition, from baseline until week 4. This suggests the efficacy of LX1031 is related to the extent of inhibition of 5-HT biosynthesis. Stool consistency significantly improved, compared with the group given placebo, at weeks 1 and 4 (P < .01) and at week 2 (P < .001). CONCLUSIONS In a phase 2 study, LX1031 was well tolerated, relieving symptoms and increasing stool consistency in patients with nonconstipating IBS. Symptom relief was associated with reduced levels of 5-HIAA in urine samples. This marker might be used to identify patients with nonconstipating IBS who respond to inhibitors of 5-HT synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
Self-citationGershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
Self-citationPostinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Maternal serotonin is crucial for murine embryonic development
Côté, F., Fligny, C., Bayard, E., Launay, J.-M., Gershon, M. D., Mallet, J., & Vodjdani, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606722104 · Cited by 381
Self-citationWheatcroft, J., Wakelin, D., Smith, A., Mahoney, C. R., Mawe, G., & Spiller, R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00719.x · Cited by 205
Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice
Gutknecht, L., Waider, J., Kraft, S., Kriegebaum, C., Holtmann, B., Reif, A., Schmitt, A., & Lesch, K.-P. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0096-6 · Cited by 173
Infection, inflammation, and the irritable bowel syndrome
Spiller, R., & Garsed, K. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.07.007 · Cited by 122
Cited by
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
“Possibly, the loss of particular TJ proteins such as occludin is a result of increased proteasome-mediated degradation observed in IBS triggered by low-grade inflammation and resulting in increased intestinal permeability [196].”
BackgroundInfluentialSerotonin signalling in the gut: functions, dysfunctions and therapeutic targets
Mawe, G. M., & Hoffman, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.105 · Cited by 1,165
5-Hydroxytryptamine (serotonin) in the gastrointestinal tract
Gershon, M. D. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835bc703 · Cited by 617
Self-citationImpact of psychological stress on irritable bowel syndrome
Qin, H.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14126 · Cited by 398
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citationA randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A., Hall, I., Whorwell, P., & Spiller, R. (2014) · Gut · doi:10.1136/gutjnl-2013-305989 · Cited by 246
IBS and IBD — separate entities or on a spectrum?
Spiller, R., & Major, G. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.141 · Cited by 163
Distrutti, E., Cipriani, S., Mencarelli, A., Renga, B., & Fiorucci, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063893 · Cited by 107
“A phase 2 clinical trial with the tryptophan hydroxylase 1 inhibitor LX1031 in patients with non-constipating IBS has been recently reported [46].”
Gross Margolis, K., Vittorio, J., Talavera, M., Gluck, K., Li, Z., Iuga, A., Stevanovic, K., Saurman, V., Israelyan, N., Welch, M. G., et al. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00215.2017 · Cited by 28
“The expression of SERT in both mucosa and ENS, however, means that additional information is needed to establish the cellular source of the responsible 5-HT.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Brown, P. M., Drossman, D. A., Wood, A. J. J., Cline, G. A., Frazier, K. S., Jackson, J. I., Bronner, J., Freiman, J., Zambrowicz, B., Sands, A., & Gershon, M. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 141
- Issue
- 2
- Pages
- 507-516
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1987488421
- Cited by
- 103
- References
- 8
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.